Staar Surgical Co. Aktie
Staar Surgical Co. Aktie
Was spricht für und gegen Staar Surgical Co. in den nächsten Jahren?
Pro
Kontra
Rendite von Staar Surgical Co. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | -2,39 % | -3,26 % | 15,52 % | -32,54 % | 46,16 % | -63,15 % | - |
Orasure Tech | -1,60 % | 0,82 % | -10,55 % | -20,00 % | -33,96 % | -34,92 % | -42,82 % |
scPharmaceuticals | -1,43 % | 1,97 % | -5,48 % | -56,88 % | -28,00 % | -21,89 % | - |
SI-BONE Inc | -0,75 % | 1,53 % | -6,34 % | -38,43 % | -30,00 % | -54,14 % | - |
Kommentare
News
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today